成功的代价：分子靶向药物的成本效益

The price of success: cost-effectiveness of molecularly targeted agents.

作者信息

Sleijfer S, Verweij J

机构信息

Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.

出版信息

Clin Pharmacol Ther. 2009 Feb;85(2):136-8. doi: 10.1038/clpt.2008.245.

DOI:10.1038/clpt.2008.245

PMID:19151639

Abstract

The advent of molecularly targeted agents has brought major breakthroughs in oncology. However, because these drugs are expensive and financial resources are limited, attention to their cost-effectiveness is rapidly increasing. It seems that establishment of cost-effectiveness is complex but is determined for the most part by the cost of drug acquisition and the drug's efficacy. This article examines the cost-effectiveness of molecularly targeted drugs.

摘要

分子靶向药物的出现给肿瘤学带来了重大突破。然而，由于这些药物价格昂贵且财政资源有限，对其成本效益的关注正在迅速增加。成本效益的确定似乎很复杂，但在很大程度上取决于药物采购成本和药物疗效。本文探讨了分子靶向药物的成本效益。